Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634244 · ClinicalTrials.gov registry record · Phase 2
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 study of Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 20
- Study locations
NCT00634244 is a Phase 2 study of Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 92 participants, below the 116-participant average among 29 other Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00634244, a Phase 2 study of Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial is comparing three different combination chemotherapy regimens to see how well they work in treating patients with relapsed or refractory acute myeloid leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients with relapsed or refractory acute myeloid leukemia.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG sirolimus
- DRUG cytarabine
- DRUG alvocidib
- DRUG mitoxantrone hydrochloride
Study Locations (20)
Pennsylvania
- Geisinger Medical Center - Danville
- Geisinger Medical Center-Cancer Center Hazleton - Hazleton
- Penn State Milton S Hershey Medical Center - Hershey
- Lewistown Hospital - Lewistown
- Geisinger Medical Group - State College
- Mount Nittany Medical Center - State College
- Geisinger Wyoming Valley - Wilkes-Barre
Wisconsin
- University of Wisconsin Hospital and Clinics - Madison
- Froedtert and the Medical College of Wisconsin - Milwaukee
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Illinois
- Northwestern University - Chicago
Iowa
- Siouxland Hematology Oncology Associates - Sioux City
Maryland
- Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2008-10 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00634244
The ClinicalTrials.gov registry entry for NCT00634244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 29 other Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities trials with a reported enrollment target (21% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities appearing as the primary indexed condition, and to 5 interventions - of which carboplatin is the first listed.
NCT00634244 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Pennsylvania, Wisconsin, Alabama.
Frequently Asked Questions
What is clinical trial NCT00634244 about?
NCT00634244 is a clinical study titled "Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This randomized phase II trial is comparing three different combination chemotherapy regimens to see how well they work in treating patients with relapsed or refractory acute myeloid leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the...
What is the current status of trial NCT00634244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2008-10. Estimated completion is 2014-10.
What conditions does trial NCT00634244 study?
This clinical trial studies the following conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Minimally Differentiated Myeloid Leukemia (M0).
What interventions are being tested in trial NCT00634244?
The interventions under investigation include: carboplatin (DRUG), sirolimus (DRUG), cytarabine (DRUG), alvocidib (DRUG), mitoxantrone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00634244?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00634244 being conducted?
This trial has 20 study locations across Alabama, Arizona, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
ACTIVE NOT RECRUITING · Phase 2
-
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
COMPLETED · Phase 2
-
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
COMPLETED · Phase 2
-
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
COMPLETED · Phase 2
-
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
All registered trials for this condition
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.